Amgen Inc., recently decided to acquire Micromet Inc. (NASDAQ:MITI) for the amount of $1.16 billion, faced a drop after announcing lower-than-estimated profit for the fourth quarter because of a decline in its anemia drugs sales while Micromet shares led biotechnology stocks on this decision as soared 32.13% to $10.94.

Other major biotechnology NASDAQ gainers with over 1 million trading shares in last session were OXiGENE, Inc. (NASDAQ:OXGN) up 24.53%, Geron Corporation (NASDAQ:GERN) rose 19.54%, StemCells, Inc. (NASDAQ:STEM) increased 12.81% and MannKind Corporation (NASDAQ:MNKD) climbed 10.36%.

On the flip side, Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA) dropped 20% to $15.13 to suffer the top decline in the Russell 2000 Index, Spectrum Pharmaceuticals, Inc. (NASDAQ:SPPI) fell 6.27%, BioSante Pharmaceuticals, Inc. (NASDAQ:BPAX) moved down 4.41%, Dendreon Corporation (NASDAQ:DNDN) decreased 3.13% and InterMune, Inc. (NASDAQ:ITMN) reduced 3.07%.

Amgen, Inc. (NASDAQ:AMGN) kicked off the last session at an opening price of $69.19 and gained as much as to reach $69.19 but later by the trade end stock declined 1.63% to $68.08.

On the other hand, its trade volume of 7.04 million shares was slightly lower than average trading capacity of 7.05 million shares. The company’s week performance emerged as -1.53%, 1 year performance moved at +20.54%, and year-to-date performance appeared positive with +6.03% while a month-performance after last trade close went up at +6.89%.

The stock price volatility was 2.12% for a week and 1.83% for a month as well as price volatility’s Average True Range for 14 days was 1.33 and its beta remained 0.46.

AMGN generated revenue of $15.45 billion in the following twelve months and earned $3.77 billion. The Company showed a positive +24.41% in the net profit margin and its operating margin which remained +27.30%. Company’s annual sales growth for the past five years was 3.90%.

The liquidity measure in recent quarter results of the company was recorded +4.60 as current ratio and on the other side the debt to equity ratio was -0.61 while long-term debt to equity ratio remained -0.59. AMGN had a cash of $20.17 per share and a book value per share as $26.79 in the most recent quarter.

THIS IS NOT A RECOMMENDATION TO BUY OR SELL ANY SECURITY!

Disclaimer: Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. galaxystocks.com publisher and its affiliates and contractors are not registered investment advisers or broker/dealers. Our disclaimer ( http://galaxystocks.com/disclaimer) is to be read and fully understood before using our site, reading our newsletter or joining our email list. Release of Liability: Through use of this website viewing or using, you agree to hold galaxystocks.com report and Crown Equity Holdings Inc. CRWE, its operators, shareholders, employees and/or contractors harmless and to completely release them from any and all liability due to any and all loss (monetary or otherwise), damages (monetary or otherwise) that you may occur. Rule 17B requires disclosure of payment for investor relations. Crown Equity Holdings Inc. (CRWE.OB) is a media-advertisement and newswire company. Crown Equity Holdings Inc. (CRWE.OB), in some cases, provides media advertising and public awareness for both public and private companies, as well as disseminating news. As such, in some cases, when Crown Equity Holdings Inc. (CRWE.OB) advertises for a particular client, Crown Equity Holdings Inc. (CRWE.OB) charges an advertising fee which it must disclose under 17B. The fee may be in cash, in free trading stock or in restricted stock. Crown Equity Holdings Inc. (CRWE.OB), if paid in stock, can and may sell those securities during the advertising period.